Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma

19 Jun 2023

Abstract excerpt

Introduction: KRAS mutation is a common occurrence in Pancreatic Ductal Adenocarcinoma (PDA) and is a driver mutation for disease development and progression. KRAS wild-type PDA may constitute a distinct molecular and clinical subtype. We used the Foundation one data to analyze the difference in Genomic Alterations (GAs) that occur in KRAS mutated and wild-type PDA. Methods: Comprehensive genomic profiling (CGP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pancreatic and Hepatic Oncology Research
Share to Pancreatic function and diabetes
Share to Pancreatitis Pathology and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37404765
DOI: 10.3389/fonc.2023.1169586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaPMID 37404765Read ↗

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.Semantic proximity Read ↗

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read ↗

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genesSemantic proximity Read ↗

Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersSemantic proximity Read ↗

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survivalSemantic proximity Read ↗

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Genetic landscape of pancreatic cancer: a narrative review.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical ImpactSemantic proximity Read ↗

Molecular Pathology of Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.